Last reviewed · How we verify

NCT05727956

Salvage Surgeries for Splanchnic Artery Aneurysms After Failed Endovascular Therapies: Cases Series

Completed Last updated 14 February 2023
What this trial tests

trial testing Aneurysmectomy in Failure in Endovascular Therapy in 5 participants. Completed in 3 February 2023.

Timeline
9 August 2019
Primary endpoint
20 January 2023
3 February 2023

Quick facts

Lead sponsorChina Medical University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment5
Start date9 August 2019
Primary completion20 January 2023
Estimated completion3 February 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

China Medical University Hospital

Who can join

Eligibility, any sex, with Failure in Endovascular Therapy or Splanchnic Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective review was performed for consecutive patients (from 2019 to 2021) who underwent salvage surgeries following failed endovascular therapies for splanchnic artery aneurysms in a tertiary referral center. Salvage operations include total aneurysmectomy with vascular reconstruction and partial aneurysmectomy with directly closing bleeders from the intraluminal space of the aneurysms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other China Medical University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05727956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing